The University of Georgia has signed a contract with the National Institutes of Health for an initial award of $8 million to develop a new, more advanced influenza vaccine designed to protect against multiple strains of influenza virus in a single dose. The total funding could be up to $130 million over seven years if all contract options are exercised.
CVM faculty member and Georgia Research Alliance Eminent Scholar of Infectious Disease Ted Ross will lead one of NIH’s new, prestigious Collaborative Influenza Vaccine Innovation Centers (CIVICs) and collaborate with teams from 14 other universities and research institutes to create and test new vaccines that may one day replace seasonal vaccines administered every year during flu season. Read the full story.
See recent news coverage of this story:
